Squarepoint
NPCE icon

Squarepoint’s Neuropace NPCE Stock Holding History

Squarepoint’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Sell
21,265
-8,671
-29% -$140K ﹤0.01% 3720
2026
Q1 		$394K Buy
29,936
+1,919
+7% +$28.8K ﹤0.01% 3501
2025
Q4 		$433K Sell
28,017
-33,580
-55% -$449K ﹤0.01% 3326
2025
Q3 		$635K Buy
61,597
+31,267
+103% +$295K ﹤0.01% 3045
2025
Q2 		$338K Buy
+30,330
New +$379K ﹤0.01% 3599
2024
Q2 		– Sell
-13,316
Closed -$176K – 4463
2024
Q1 		$176K Buy
+13,316
New +$190K ﹤0.01% 3652

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Squarepoint's NPCE Position: Q2 2026 in Review

Squarepoint reduced its Neuropace (NPCE) stake by 29% in Q2 2026, selling an estimated $140K and leaving 21,265 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #3720.

Squarepoint first reported a position in NPCE in Q1 2024 and has held it in 6 quarters since. The position peaked at $635K in Q3 2025. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Squarepoint held 21,265 shares of Neuropace worth $338K as of Q2 2026.
  • Squarepoint sold 8,671 Neuropace shares in Q2 2026, an estimated $140K.
  • Neuropace made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3720 holding.
  • Squarepoint first reported a position in Neuropace in Q1 2024 and has held it in 6 quarters since.
  • Squarepoint's Neuropace position peaked at $635K in Q3 2025.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.